Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash from Financing Activities (2018 - 2025)

BioNexus Gene Lab's Cash from Financing Activities history spans 8 years, with the latest figure at $34187.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 161.07% year-over-year to $34187.0; the TTM value through Sep 2025 reached $30910.0, down 95.44%, while the annual FY2024 figure was $144975.0, 97.69% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $34187.0 at BioNexus Gene Lab, up from -$1030.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.7 million in Q3 2023 and bottomed at -$55982.0 in Q3 2024.
  • The 5-year median for Cash from Financing Activities is -$1561.5 (2022), against an average of $362897.6.
  • The largest annual shift saw Cash from Financing Activities crashed 378.18% in 2021 before it surged 331172.47% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$4959.0 in 2021, then surged by 54.16% to -$2273.0 in 2022, then soared by 23493.44% to $531733.0 in 2023, then tumbled by 100.26% to -$1387.0 in 2024, then skyrocketed by 2564.82% to $34187.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Cash from Financing Activities are $34187.0 (Q3 2025), -$1030.0 (Q2 2025), and -$860.0 (Q1 2025).